Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: A replication and extension study

Brain, Behavior, and Immunity

Volumn 30, Issue SUPPL., 2013, Pages

  McDonald, Brenna C ^a   Conroy, Susan K ^a   Smith, Dori J ^a   West, John D ^a   Saykin, Andrew J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adjuvant chemotherapy; APOE genotype; Brain; Breast cancer; BRIEF A; Executive function; Frontal lobes; Magnetic resonance imaging; Neuroimaging; Voxel based morphometry

Indexed keywords

APOLIPOPROTEIN E; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; PACLITAXEL;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; COGNITION; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; EXECUTIVE FUNCTION; FEMALE; GENE FREQUENCY; GENOTYPE; GRAY MATTER; HETEROZYGOTE; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SELF REPORT; VOXEL BASED MORPHOMETRY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATROPHY; BREAST NEOPLASMS; COGNITION DISORDERS; EXECUTIVE FUNCTION; FEMALE; FRONTAL LOBE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEUROIMAGING; NEUROPSYCHOLOGICAL TESTS; ORGAN SIZE;

EID: 84875373005     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2012.05.007     Document Type: Article

References (53)

1. Agrawal K., Onami S., Mortimer J.E., Pal S.K. Cognitive changes associated with endocrine therapy for breast cancer. Maturitas 2010, 67:209-214.
2. Ahles T.A., Saykin A.J. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat. Rev. Cancer 2007, 7:192-201.
3. Ahles T.A., Saykin A.J., McDonald B.C., Furstenberg C.T., Cole B.F., Hanscom B.S., Mulrooney T.J., Schwartz G.N., Kaufman P.A. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res. Treat. 2008, 110:143-152.
4. Ahles T.A., Saykin A.J., McDonald B.C., Li Y., Furstenberg C.T., Hanscom B.S., Mulrooney T.J., Schwartz G.N., Kaufman P.A. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J. Clin. Oncol. 2010, 28:4434-4440.
5. Ahles T.A., Saykin A.J., Noll W.W., Furstenberg C.T., Guerin S., Cole B., Mott L.A. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology 2003, 12:612-619.
6. Anderson-Hanley C., Sherman M.L., Riggs R., Agocha V.B., Compas B.E. Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J. Int. Neuropsychol. Soc. 2003, 9:967-982.
7. Ashburner J., Friston K.F. Voxel-based morphometry - the methods. Neuroimage 2000, 11:805-821.
8. Ashburner J., Friston K.J. Why voxel-based morphometry should be used. Neuroimage 2001, 14:1238-1243.
9. Barona A., Reynolds C., Chastain R. A demographically based index of pre-morbid intelligence for the WAIS-R. J. Consult. Clin. Psychol. 1984, 52:885-887.
10. Bookheimer S., Burggren A. APOE-4 genotype and neurophysiological vulnerability to Alzheimer's and cognitive aging. Annu 2009, 5:343-362.
11. Chang N.-W., Chen D.-R., Wu C.-T., Aouizerat B.E., Chen F.-N., Hung S.-J., Wang S.-H., Wei M.-F., Chang C.-S. Influences of apolipoprotein E polymorphism on the risk for breast cancer and HER2/neu status in Taiwan. Breast Cancer Res. Treat. 2005, 90:257-261.
12. Chang S.-J., Hou M.-F., Tsai S.-M., Kao J.-T., Wu S.-H., Hou L.A., Tsai L.-Y. Association between the apolipoprotein E genotypes and breast cancer patients in Taiwanese. Breast Cancer Res. Treat. 2006, 98:109-113.
13. Cimprich B., Reuter-Lorenz P., Nelson J., Clark P.M., Therrien B., Normolle D., Berman M.G., Hayes D.F., Noll D.C., Peltier S., Welsh R.C. Prechemotherapy alterations in brain function in women with breast cancer. J. Clin. Exp. Neuropsychol. 2010, 32:324-331.
14. Collins B., Mackenzie J., Stewart A., Bielajew C., Verma S., Collins B., Mackenzie J., Stewart A., Bielajew C., Verma S. Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. Psychooncology 2009, 18:134-143.
15. Correa D.D., Ahles T.A. Neurocognitive changes in cancer survivors. Cancer J. 2008, 14:396-400.
16. de Ruiter, M.B., Reneman, L., Boogerd, W., Veltman, D.J., Caan, M., Douaud, G., Lavini, C., Linn, S.C., Boven, E., van Dam, F.S.A.M., Schagen, S.B., in press, epub ahead of print. Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging. Hum Brain Mapp.
17. de Ruiter M.B., Reneman L., Boogerd W., Veltman D.J., van Dam F.S.A.M., Nederveen A.J., Boven E., Schagen S.B. Cerebral hyporesponsiveness and cognitive impairment 10years after chemotherapy for breast cancer. Hum. Brain Mapp. 2011, 32:1206-1219.
18. Farrer L.A., Cupples L.A., Haines J.L., Hyman B., Kukull W.A., Mayeux R., Myers R.H., Pericak-Vance M.A., Risch N., van Duijn C.M. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer disease meta analysis consortium. JAMA 1997, 278:1349-1356.
19. Garlinghouse M.A., Roth R.M., Isquith P.K., Flashman L.A., Saykin A.J. Subjective rating of working memory is associated with frontal lobe volume in schizophrenia. Schizophr. Res. 2010, 120:71-75.
20. Good C.D., Johnsrude I.S., Ashburner J., Henson R.N., Friston K.J., Frackowiak R.S. A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage 2001, 14:21-36.
21. Hakamata Y., Matsuoka Y., Inagaki M., Nagamine M., Hara E., Imoto S., Murakami K., Kim Y., Uchitomi Y. Structure of orbitofrontal cortex and its longitudinal course in cancer-related post-traumatic stress disorder. Neurosci. Res. 2007, 59:383-389.
22. Inagaki M., Yoshikawa E., Matsuoka Y., Sugawara Y., Nakano T., Akechi T., Wada N., Imoto S., Murakami K., Uchitomi Y. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 2007, 109:146-156.
23. Jansen C.E., Cooper B.A., Dodd M.J., Miaskowski C.A. A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Support. Care Cancer 2011, 19:1647-1656.
24. Jenkins V., Shilling V., Deutsch G., Bloomfield D., Morris R., Allan S., Bishop H., Hodson N., Mitra S., Sadler G., Shah E., Stein R., Whitehead S., Winstanley J. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Brit J Cancer 2006, 94:828-834.
25. Jim H.S.L., Donovan K.A., Small B.J., Andrykowski M.A., Munster P.N., Jacobsen P.B. Cognitive functioning in breast cancer survivors: a controlled comparison. Cancer 2009, 115. 1776-1183.
26. Kesler S.R., Bennett F.C., Mahaffey M.L., Spiegel D. Regional brain activation during verbal declarative memory in metastatic breast cancer. Clin. Cancer Res. 2009, 15:6665-6673.
27. Kesler S.R., Kent J.S., O'Hara R. Prefrontal cortex and executive function impairments in primary breast cancer. Arch. Neurol. 2011, 68:1447-1453.
28. Koppelmans V., de Ruiter M.B., van der Lijn F., Boogerd W., Seynaeve C., van der Lugt A., Vrooman H., Niessen W.J., Breteler M.M.B., Schagen S.B. Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy. Breast Cancer Res. Treat. 2012, 132:1099-1106.
29. McDonald B.C., Conroy S.K., Ahles T.A., West J.D., Saykin A.J. Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res. Treat. 2010, 123:819-828.
30. McDonald, B.C., Conroy, S.K., Ahles, T.A., West, J.D., Saykin, A.J., in press. Alterations in brain activation during working memory processing associated with breast cancer and treatment: a prospective functional MRI study. J. Clin. Oncol.
31. McDonald B.C., Saykin A.J. Neurocognitive dimensions of breast cancer and its treatment. Neuropsychopharmacology 2011, 36:355-356.
32. McDonald B.C., Saykin A.J., Ahles T.A. Brain imaging investigation of chemotherapy-induced neurocognitive changes. Cognition and Cancer 2008, 19-32. Cambridge University Press, Cambridge, MA. C.A. Meyers, J.R. Perry (Eds.).
33. Moysich K.B., Freudenheim J.L., Baker J.A., Ambrosone C.B., Bowman E.D., Schisterman E.F., Vena J.E., Shields P.G. Apolipoprotein E genetic polymorphism, serum lipoproteins, and breast cancer risk. Mol. Carcinog. 2000, 27:2-9.
34. Niemi M., Kervinen K., Kiviniemi H., Lukkarinen O., Kyllonen A.P., Apaja-Sarkkinen M., Savolainen M.J., Kairaluoma M.I., Kesaniemi Y.A. Apolipoprotein E phenotype, cholesterol and breast and prostate cancer. J. Epidemiol. Community Health 2000, 54:938-939.
35. Porrata-Doria T., Matta J.L., Acevedo S.F. Apolipoprotein E allelic frequency altered in women with early-onset breast cancer. Breast cancer 2010, 4:43-48.
36. Quesnel C., Savard J., Ivers H., Quesnel C., Savard J., Ivers H. Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Cancer Res. Treat. 2009, 116:113-123.
37. Radloff L.S. The CES-D Scale: A self-report depression scale for research in the general population. Appl. Psychol. Meas. 1977, 1:385-401.
38. Roth R.M., Isquith P.K., Gioia G.A. BRIEF-A Behavior Rating Inventory of Executive Function-Adult Version Professional Manual 2005, Psychological Assessment Resources, Inc., Lutz, FL.
39. Saykin A.J., Ahles T.A., McDonald B.C. Mechanisms of chemotherapy-induced cognitive disorders: neuropsychological, pathophysiological, and neuroimaging perspectives. Semin Clin Neuropsychiatry 2003, 8:201-216.
40. Schagen S.B., Das E., van Dam F.S.A.M. The influence of priming and pre-existing knowledge of chemotherapy-associated cognitive complaints on the reporting of such complaints in breast cancer patients. Psychooncology 2009, 18:674-678.
41. Schagen S.B., Muller M.J., Boogerd W., Rosenbrand R.M., van Rhijn D., Rodenhuis S., van Dam F.S. Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann. Oncol. 2002, 13:1387-1397.
42. Scherling C., Collins B., Mackenzie J., Bielajew C., Smith A. Pre-chemotherapy differences in visuospatial working memory in breast cancer patients compared to controls: an FMRI study. Front. Hum. Neurosci. 2011, 5:122.
43. Scherling C., Collins B., Mackenzie J., Bielajew C., Smith A. Prechemotherapy differences in response inhibition in breast cancer patients compared to controls: a functional magnetic resonance imaging study. J. Clin. Exp. Neuropsychol. 2012, 34:543-560.
44. Silverman D.H., Dy C.J., Castellon S.A., Lai J., Pio B.S., Abraham L., Waddell K., Petersen L., Phelps M.E., Ganz P.A. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10years after chemotherapy. Breast Cancer Res. Treat. 2007, 103:303-311.
45. Small B.J., Rawson K.S., Walsh E., Jim H.S.L., Hughes T.F., Iser L., Andrykowski M.A., Jacobsen P.B. Catechol-O-methyltransferase genotype modulates cancer treatment-related cognitive deficits in breast cancer survivors. Cancer 2011, 117:1369-1376.
46. Smith J.D. Apolipoprotein E4: an allele associated with many diseases. Ann. Med. 2000, 32:118-127.
47. Spielberger C.D. State-Trait Anxiety Inventory 1983, Consulting Psychologists Press, Inc., Palo Alto, CA.
48. Stewart A., Bielajew C., Collins B., Parkinson M., Tomiak E. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin. Neuropsychol. 2006, 20:76-89.
49. Vardy J., Wefel J.S., Ahles T., Tannock I.F., Schagen S.B. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann. Oncol. 2008, 19:623-629.
50. Wagner L., Sweet J., Butt Z., Beaumont J., Havlin K., Sabatino T., Cella D. Trajectory of cognitive impairment during breast cancer treatment: a prospective analysis. J. Clin. Oncol. 2006, 24:S8500.
51. Wefel J.S., Lenzi R., Theriault R., Buzdar A.U., Cruickshank S., Meyers C.A. 'Chemobrain' in breast carcinoma? A prologue. Cancer 2004, 101:466-475.
52. Yaylim I., Bozkurt N., Yilmaz H., Isbir T., Isik N., Arikan S. The apolipoprotein E epsilon 4 allele is not a risk factor for Turkish breast cancer patients. Cancer Genet. Cytogenet. 2003, 146:86-87.
53. Yoshikawa E., Matsuoka Y., Yamasue H., Inagaki M., Nakano T., Akechi T., Kobayakawa M., Fujimori M., Nakaya N., Akizuki N., Imoto S., Murakami K., Kasai K., Uchitomi Y. Prefrontal cortex and amygdala volume in first minor or major depressive episode after cancer diagnosis. Biol. Psychiatry 2006, 59:707-712.